V. Racloz and S. Luiz, The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology, BMC Infectious Diseases, vol.38, issue.12, p.175, 2010.
DOI : 10.1128/JCM.41.12.5783-5786.2003

S. Nadel, Prospects for eradication of meningococcal disease, Archives of Disease in Childhood, vol.97, issue.11, pp.993-1001, 2012.
DOI : 10.1136/archdischild-2012-302036

. Méningite-À-méningocoques, Aide-mémoire n°141 OMS, Novembre 2012

A. Sabra and J. Benger, Meningococcal disease in children: a clinical review, Turk J Pediatr, vol.53, pp.477-88, 2011.

M. Taha, A. Deghmane, and A. Antignac, The duality of virulence and transmissibility in Neisseria meningitidis, Trends in Microbiology, vol.10, issue.8, pp.376-82, 2002.
DOI : 10.1016/S0966-842X(02)02402-2

L. Harrison, C. Trotter, and M. Ramsay, Global epidemiology of meningococcal disease, Vaccine, vol.27, pp.51-63, 2009.
DOI : 10.1016/j.vaccine.2009.04.063

M. Dommergues, Les vaccins m??ningococciques de s??rogroupe B, Archives de P??diatrie, vol.19, pp.65-74, 2012.
DOI : 10.1016/S0929-693X(12)71276-9

E. Watkins and M. Maiden, Persistence of Hyperinvasive Meningococcal Strain Types during Global Spread as Recorded in the PubMLST Database, PLoS ONE, vol.7, issue.9, p.45349, 2012.
DOI : 10.1371/journal.pone.0045349.s002

M. Van-deuren, P. Brandtzaeg, and J. Van-der-meer, Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management, Clinical Microbiology Reviews, vol.13, issue.1, pp.144-66, 2000.
DOI : 10.1128/CMR.13.1.144-166.2000

M. Taha and A. Deghmane, New recombinant vaccines for the prevention of meningococcal B disease, Vaccine: Development and Therapy, vol.2, pp.15-22, 2012.
DOI : 10.2147/VDT.S25458

H. Claus, M. Maiden, and D. Wilson, Genetic Analysis of Meningococci Carried by Children and Young Adults, The Journal of Infectious Diseases, vol.191, issue.8, pp.1263-71, 2005.
DOI : 10.1086/428590

A. Petterson, J. Poolman, and P. Van-der-ley, Response of Neisseria meningitidis to iron limitation, Antonie van Leeuwenhoek, vol.71, issue.1/2, pp.129-165, 1997.
DOI : 10.1023/A:1000179301748

L. Harrison, Prospects for Vaccine Prevention of Meningococcal Infection, Clinical Microbiology Reviews, vol.19, issue.1, pp.142-64, 2006.
DOI : 10.1128/CMR.19.1.142-164.2006

M. Thompson, Clinical recognition of meningococcal disease in children and adolescents, The Lancet, vol.367, issue.9508, pp.397-403, 2006.
DOI : 10.1016/S0140-6736(06)67932-4

S. Rajapaksa and M. Starr, Meningococcal sepsis, Australian Family Physician, vol.39, pp.276-284, 2010.

D. Panatto, D. Amicizia, and P. Lai, B vaccines, Expert Review of Vaccines, vol.10, issue.9, pp.1337-51, 2011.
DOI : 10.1586/erv.11.103

C. Buysse, A. Oranje, and E. Zuidema, Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock, Archives of Disease in Childhood, vol.94, issue.5, pp.381-387, 2009.
DOI : 10.1136/adc.2007.131862

M. Girard, M. Preziosi, and M. Aguado, A review of vaccine research and development: Meningococcal disease???, Vaccine, vol.24, issue.22, pp.24-4692, 2006.
DOI : 10.1016/j.vaccine.2006.03.034

C. Levy, M. Taha, and C. Olivier, Caract??ristiques des m??ningites ?? m??ningocoque de l'enfant en France, Archives de P??diatrie, vol.15, pp.105-115, 2008.
DOI : 10.1016/S0929-693X(08)75492-7

A. Barret, A. Deghmane, and A. Lepoutre, Les infections invasives à méningocoques en France en 2012 : principales caractéristiques épidémiologiques, Bull Epidémiol Hebd, issue.12, pp.25-31, 2014.

H. Conseil-de-la-santé-publique, Avis relatif à l'antibioprophylaxie et la vaccination méningococcique des personnes traitées par éculizumab (Soliris® 300mg solution à diluer pour perfusion), 2012.

C. Fijen, E. Kuijper, and J. Dankert, Complement characterization of Neisseria meningitidis strains causing disease in complement-deficient and complement-sufficient patients, J Clin Microbiol, vol.36, p.2342, 1998.

I. N°-dgs-/-ri1, 33 du 27 janvier 2011 relative à la prophylaxie des infections invasives à méningocoque. Ministère du travail, de l'emploi et de la santé, 2011.

F. Berger, I. Parent-du-chatelet, and P. Bernillon, Surveillance des infections invasives à méningocoque en France métropolitaine en Évaluation quantitative par la méthode de capture-recapture à trois sources Saint-Maurice : Institut de veille sanitaire, 2005.

C. Levy, M. Taha, and E. Bingen, M??ningites ?? m??ningocoques de l???enfant en France: r??sultats de l???observatoire ACTIV/GPIP, Archives de P??diatrie, vol.19, pp.49-54, 2012.
DOI : 10.1016/S0929-693X(12)71273-3

I. Goldschneider, E. Gotschlich, and M. Artenstein, HUMAN IMMUNITY TO THE MENINGOCOCCUS: I. THE ROLE OF HUMORAL ANTIBODIES, Journal of Experimental Medicine, vol.129, issue.6, pp.1307-1333, 1969.
DOI : 10.1084/jem.129.6.1307

M. Eckhardt, M. Muhlenhoff, and A. Bethe, Molecular characterization of eukaryotic polysialyltransferase-1, Nature, vol.373, issue.6516, pp.715-723, 1995.
DOI : 10.1038/373715a0

J. Finne, D. Bitter-suermann, C. Goridis, and U. Finne, An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues, J Immunol, vol.138, pp.4402-4409, 1987.

J. Holst, B. Feiring, and L. Naess, The concept of ?tailor-made?, protein-based, outer membrane vesicle vaccines against meningococcal disease, Vaccine, vol.23, issue.17-18, pp.2202-2207, 2005.
DOI : 10.1016/j.vaccine.2005.01.058

D. Granoff, Review of Meningococcal Group B Vaccines, Clinical Infectious Diseases, vol.50, issue.s2, pp.54-65, 2010.
DOI : 10.1086/648966

P. Rouaud, A. Perrocheau, and M. Taha, Prolonged outbreak of meningococcal disease in the Seine-Maritime department, Euro Surveill, vol.11, pp.178-81, 2003.

M. Taha, M. Zarantonelli, and J. Alonso, Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks, Vaccine, vol.25, issue.14, pp.2537-2545, 2007.
DOI : 10.1016/j.vaccine.2005.12.059

I. Feavers and M. Pizza, Meningococcal protein antigens and vaccines, Vaccine, vol.27, pp.42-50, 2009.
DOI : 10.1016/j.vaccine.2009.05.001

T. Vesikari, S. Esposito, and R. Prymula, Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials, The Lancet, vol.381, issue.9869, pp.825-860, 2013.
DOI : 10.1016/S0140-6736(12)61961-8

R. Rappuoli, Reverse vaccinology, a genome-based approach to vaccine development, Vaccine, vol.19, issue.17-19, pp.2688-91, 2001.
DOI : 10.1016/S0264-410X(00)00554-5

J. Donnelly, D. Medini, and G. Boccadifuoco, Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines, Proceedings of the National Academy of Sciences, vol.107, issue.45, pp.19490-19495, 2010.
DOI : 10.1073/pnas.1013758107

U. Vogel, M. Taha, and J. Vazquez, Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment, The Lancet Infectious Diseases, vol.13, issue.5, pp.416-441, 2013.
DOI : 10.1016/S1473-3099(13)70006-9

H. Conseil-de-la-santé-publique, Avis relatif à la vaccination ciblée contre les infections invasives à méningococque liées au clone B14, P1.7,16 du complexe clonal ST-32 avec les vaccins MenBvac® et Bexsero® dans le département des Pyrénées-Atlantiques. 22 février 2013

H. Conseil-de-la-santé-publique, Avis relatif au schéma vaccinal par le vaccin MenBvac® et à une éventuelle revaccination par Bexsero®, 2014.

H. Conseil-de-la-santé-publique, Avis relatif à la nécessité de poursuivre les campagnes de vaccination contre le clone B:14:P1.7-16 en Seine-Maritime, 2014.

. Epibac and . Données, Unité des maladies à prévention vaccinale.InVS www.invs.sante.fr/surveillance, 2010.

L. Jimenez, J. , V. Florido, A. , R. De-mora et al., Utilidad de la procalcitonina, prote??na C reactiva y recuento leucocitario en la detecci??n de enfermedad meningoc??cica durante un brote epid??mico, Anales de Pediatr??a, vol.62, issue.4, pp.328-360, 2005.
DOI : 10.1157/13073245

H. Guven, L. Altintop, and A. Baydin, Diagnostic value of procalcitonin levels as an early indicator of sepsis, The American Journal of Emergency Medicine, vol.20, issue.3, pp.202-208, 2002.
DOI : 10.1053/ajem.2002.33005

D. Van-der-kaay, D. Kleijn, E. , D. Rijke, and Y. , Procalcitonin as a prognostic marker in meningococcal disease, Intensive Care Medicine, vol.28, issue.11, pp.1606-1618, 2002.
DOI : 10.1007/s00134-002-1505-1

S. Erouart, M. Martel, and C. Vanbockstael, Evaluation de la couverture vaccinale par le vaccin MenBvac® en Seine-Maritime et dans la Somme en 2013. Saint-Maurice: Institut de veille sanitaire;2014.31p. Disponible à partir de l

F. Caron, V. Delbos, and A. Deghmane, Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac, Vaccine, vol.30, issue.34, pp.5059-62, 2012.
DOI : 10.1016/j.vaccine.2012.05.051

H. Conseil-de-la-santé-publique, Avis, Actualisation de l'avis relatif à l'antibioprophylaxie et la vaccination méningococcique des personnes traitées par éculizumab (Soliris® 300mg solution à diluer pour perfusion), 2014.

D. Générale-de and L. Santé, département des situations d'urgence sanitaire. Retour d'expérience, Hyper-endémie d'infections invasives à méningocoque B en Seine-Maritime, 2007.

H. Conseil-de-la-santé-publique, Vaccination contre les infections invasives à méningocoque B : place du vaccin Bexsero®, 2013.

H. Conseil-de-la-santé-publique, Aluminium et vaccins, Rapport, 2013.

E. Touzé, O. Gout, and M. Verdier-taillefer, First central nervous system demyelination and hepatitis B vaccination : a pilot case-control study, Rev Neurol, vol.156, pp.242-248, 2000.

F. Zipp, J. Weil, and K. Einhaupl, No increase in demyelinating diseases after hep atitis B vaccination, Nature Medicine, vol.5, issue.9, pp.964-969, 1999.
DOI : 10.1038/12376

A. Ascherio, S. Zhang, and M. Hernan, Hepatitis B Vaccination and the Risk of Multiple Sclerosis, New England Journal of Medicine, vol.344, issue.5, pp.327-359, 2001.
DOI : 10.1056/NEJM200102013440502

A. Sadnovick and D. Scheifele, School-based hepatitis B vaccination programme and adolescent multiple sclerosis, Lancet, vol.355, pp.549-50, 2000.

C. Baker and M. Snape, Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action, The Lancet Infectious Diseases, vol.14, issue.3, pp.227-265, 2014.
DOI : 10.1016/S1473-3099(13)70238-X

G. Zimet, Z. Rosberger, and W. Fisher, Beliefs, behaviors and HPV vaccine: Correcting the myths and the misinformation, Preventive Medicine, vol.57, issue.5, pp.414-422, 2013.
DOI : 10.1016/j.ypmed.2013.05.013

P. Bégué, Vaccine refusal and implications for public health in 2012, Bull Acad Natl Med, vol.201196, pp.603-620

D. Panatto, D. Amicizia, and P. Lai, New versus old meningococcal Group B vaccines: How the new ones may benefit infants & toddlers, Indian J Med Res, vol.138, pp.835-881, 2013.

S. Harris, D. Zhu, and E. Murphy, Serogroup C Disease, Human Vaccines, vol.7, issue.sup1, pp.68-74, 2011.
DOI : 10.1074/jbc.M808831200

R. Cohen, C. Levy, and S. Bechet, Comment p??diatres et g??n??ralistes envisagent-ils l???introduction d???une vaccination contre le m??ningocoque B en France???, Archives de P??diatrie, vol.19, issue.12, pp.1379-85, 2012.
DOI : 10.1016/j.arcped.2012.10.001

P. Bakhache, C. Rodrigo, and D. S. , Health care providers??? and parents??? attitudes toward administration of new infant vaccines???a multinational survey, European Journal of Pediatrics, vol.27, issue.4, pp.485-92, 2013.
DOI : 10.1007/s00431-012-1904-4

C. Auckland, S. Gray, and R. Borrow, Clinical and Immunologic Risk Factors for Meningococcal C Conjugate Vaccine Failure in the United Kingdom, The Journal of Infectious Diseases, vol.194, issue.12, pp.1745-52, 2006.
DOI : 10.1086/509619